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http://dx.doi.org/10.1016/j.ccell.2015.04.006SUMMARYMutations affecting spliceosomal proteins are the most common mutations in patients with myelodysplastic
syndromes (MDS), but their role inMDS pathogenesis has not been delineated. Herewe report that mutations
affecting the splicing factor SRSF2 directly impair hematopoietic differentiation in vivo, which is not due to
SRSF2 loss of function. By contrast, SRSF2mutations alter SRSF2’s normal sequence-specific RNA binding
activity, thereby altering the recognition of specific exonic splicing enhancer motifs to drive recurrent mis-
splicing of key hematopoietic regulators. This includes SRSF2mutation-dependent splicing of EZH2, which
triggers nonsense-mediated decay, which, in turn, results in impaired hematopoietic differentiation. These
data provide amechanistic link between a mutant spliceosomal protein, alterations in the splicing of key reg-
ulators, and impaired hematopoiesis.INTRODUCTION
Somatic mutations in genes encoding components of the spli-
ceosome have been identified in a spectrum of human malig-
nancies, including 60% of patients with myelodysplasticSignificance
Frequent somatic mutations affecting components of the splic
however, the functional role of these mutations is not known.
spliceosomal gene SRSF2 impair hematopoietic differentiatio
ence for specific exonic splicing enhancer motifs. This result
expression of abnormal isoforms of a number of key hematopo
to leukemogenesis (including BCOR and EZH2). These data pro
mutations in myelodysplasia and identify altered RNA recognisyndromes (MDS) (Bejar et al., 2012; Papaemmanuil et al.,
2013; Yoshida et al., 2011). These mutations occur most
commonly in SF3B1 (Splicing Factor 3b Subunit 1), SRSF2
(Serine/arginine-Rich Splicing Factor 2), and U2AF1 (U2 Small
Nuclear RNA Auxiliary Factor 1) and almost always aseosome have been identified in hematologic malignancies;
Here we identify that commonly occurring mutations in the
n and promote myelodysplasia by altering SRSF2’s prefer-
s in consistent mis-splicing in a manner that promotes the
ietic regulators, some of which have been linked previously
vide amechanistic basis for the enrichment of spliceosomal
tion as an important driver of leukemogenesis.
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heterozygous missense mutations that are mutually exclusive
(Papaemmanuil et al., 2011; Wang et al., 2011; Yoshida et al.,
2011). Although the genetic data in MDS suggest that these
alterations are critical to disease pathogenesis, it remains un-
known how these mutations contribute to MDS and whether
they are sufficient to induce MDS.
Recent studies have suggested that mutations in the spliceo-
somal gene U2AF1 alter RNA splicing (Brooks et al., 2014; Grau-
bert et al., 2012; Ilagan et al., 2015; Przychodzen et al., 2013;
Quesada et al., 2012), and studies of gene expression in primary
patient samples with and without U2AF1 mutations have been
performed in an effort to identify downstream mis-spliced genes
that might contribute to abnormal hematopoiesis (Brooks et al.,
2014; Graubert et al., 2012; Ilagan et al., 2015). However, it re-
mains unknown how thesemutations contribute to hematopoiet-
ic transformation. To date, no studies have investigated the
in vivo effects of spliceosomal mutations expressed from the
endogenous locus in the correct cellular context, which might
allow delineation of how these alleles contribute to MDS
pathogenesis.
To test whether spliceosomal gene mutations are sufficient to
drive MDS and determine how altered RNA splicing contributes
to transformation in vivo, we studied the biological and transcrip-
tional consequences of mutations in SRSF2. SRSF2 mutations
occur in 20%–30% of MDS and 50% of chronic myelomono-
cytic leukemia (CMML) patients (Papaemmanuil et al., 2013;
Yoshida et al., 2011). SRSF2 is a member of the serine/argi-
nine-rich (SR) protein family that contributes to both constitutive
and alternative splicing by binding to exonic splicing enhancer
(ESE) sequences within pre-mRNA through its RNA recognition
motif domain (RRM) (Graveley and Maniatis, 1998; Liu et al.,
2000; Schaal andManiatis, 1999; Zahler et al., 2004).SRSF2mu-
tations are consistently associated with adverse outcomes
among MDS and acute myeloid leukemia (AML) patients (Pa-
paemmanuil et al., 2013; Vannucchi et al., 2013; Zhang et al.,
2012). Despite the clinical importance of SRSF2 mutations, to
date there have been no studies of the functional impact of
SRSF2mutations on hematopoiesis or splicing. Here we studied
the biological and transcriptional effects of somatic expression
of the common SRSF2P95H mutation in the hematopoietic
compartment.
RESULTS
Srsf2P95H Mutant Mice Develop MDS, a Phenotype
Distinct from Mice with Heterozygous or Homozygous
Loss of Srsf2
Given the genetic heterogeneity of primary patient samples as
well as the fact that stable overexpression of spliceosomal pro-
teins, even in wild-type (WT) form, is poorly tolerated (Lareau
et al., 2007), we first generated a murine model for conditional
expression of the commonly occurring SRSF2P95H mutation
from the endogenous murine locus of Srsf2 (Figure 1A; Figures
S1A and S1B). Mice heterozygous for the Srsf2P95H allele
(Srsf2P95H/WT) were crossed to Mx1-cre transgenic mice
(Ku¨hn et al., 1995) on a C57BL/6 background to allow for induc-
ible expression of Cre recombinase following intraperitoneal in-
jection of polyinosine-polycytosine (pIpC) (12 mg/g every other
day for 3 days by injection, as described previously [Moran-Cru-618 Cancer Cell 27, 617–630, May 11, 2015 ª2015 Elsevier Inc.sio et al., 2011; Figures S1C and S1D; Supplemental Experi-
mental Procedures]). mRNA sequencing (RNA-seq) analysis of
hematopoietic stem/progenitor cells (HSPCs) 2 weeks after
the last pIpC injection of 6-week-old Mx1-cre Srsf2P95H/WT
and Mx1-cre Srsf2 WT control mice confirmed heterozygous
expression of the mutant allele in equal proportion to the re-
maining WT Srsf2 allele in Mx1-cre Srsf2P95H/WT mice
(Figure 1B).
It is currently unknownwhether the heterozygous SRSF2P95H
mutation confers a gain of function, haploinsufficient loss of
function, or dominant-negative loss of function. We therefore
compared expression of the Srsf2P95Hmutation with the condi-
tional loss of Srsf2 in vivo (Wang et al., 2001). Bone marrow (BM)
mononuclear cells (MNCs) from 6-week-old CD45.2 Mx1-cre
Srsf2 WT, Mx1-cre Srsf2fl/WT (heterozygous floxed mice for
inducible deletion of one copy of Srsf2), Mx1-cre Srsf2fl/fl (ho-
mozygous floxed mice for inducible deletion of both copies of
Srsf2), and Mx1-cre Srsf2P95H/WT were transplanted into
lethally irradiated congenic CD45.1 recipient mice, followed by
pIpC injection 4 weeks later (note that all mice were treated
with pIpC to control for any potential phenotypic effects of
pIpC administration on biological or splicing phenotypes). This
was done to assess for the phenotypic effects of Srsf2 deletion
or mutation in a hematopoietic cell-autonomous manner. West-
ern blot (WB) analysis revealed the deletion of Srsf2 in BMMNCs
fromMx1-cre Srsf2fl/fl mice and normal total Srsf2 levels inMx1-
cre Srsf2P95H/WT BM MNCs (Figure S1E). Significant leuko-
penia and anemia were seen in mice with homozygous Srsf2
deletion or heterozygous expression of the P95H mutation
18 weeks post-transplant (Figures 1C and 1D) that was also
seen at earlier time points (Figures S1F and S1G). The presence
of similar cytopenias in mice bearing a homozygous Srsf2 dele-
tion and a heterozygous Srsf2P95H point mutation suggested a
possible dominant-negative function imposed by the P95H mu-
tation. However, the anemia in Srsf2P95H mice was character-
ized by increased mean corpuscular volume (MCV) of red blood
cells relative toWTmice or mice with loss of one to two copies of
Srsf2 (Figure 1E). Moreover, histological assessment of mice
14 weeks post-pIpC revealed prominent BM aplasia in Srsf2 ho-
mozygous knockout (KO) mice, whereas mice expressing the
heterozygous P95H mutation had normal BM cellularity (Fig-
ure 1F). Platelet counts were normal in Srsf2P95H mutant mice
at all time points examined (Figure S1H).
Given that macrocytic anemia, a hallmark of anemia in MDS,
was present in Srsf2P95Hmutant mice, we next performed cyto-
logical examination of peripheral blood and bone marrow
smears from Mx1-cre Srsf2 WT, Mx1-cre Srsf2fl/fl, and Mx1-
cre Srsf2P95H/WT mice to assess for morphologic dysplasia.
This revealed prominent myeloid and erythroid dysplasia in
Srsf2P95H mice but not in Mx1-cre Srsf2 WT or Mx1-cre
Srsf2fl/fl mice (Figure 1G; Figure S1I). Myeloid dysplasia was
apparent based on detection of hypolobated and hypogranu-
lated neutrophils, whereas erythroid dysplasia was evident
based on nuclear irregularities and cytoplasmic vacuolization
and blebbing in erythroid precursors. Overall, these results indi-
cate that mutations in Srsf2P95H result in morphologic dysplasia
and cytopenias with preserved marrow cellularity, features that
are characteristic of human MDS, whereas complete loss of
Srsf2 is incompatible with hematopoiesis.
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Figure 1. Conditional Expression of Srsf2P95H Results in Myeloid Dysplasia, a Phenotype Distinct from Heterozygous or Homozygous Loss
of Srsf2
(A) Depiction of the Srsf2P95H allele.
(B) RNA-seq of LSK cells in Mx1-cre Srsf2WT and Mx1-cre Srsf2P95H/WT mice.
(C–E) White blood cell (WBC) count (C), hemoglobin (Hb) (D), and MCV (E) of red blood cells of CD45.1 recipient mice 18 weeks following noncompetitive
transplantation of bonemarrow fromCD45.2+Mx1-cre Srsf2WT,Mx1-cre Srsf2fl/WT,Mx1-cre Srsf2fl/fl, andMx1-cre Srsf2P95H/WTmice (n = 10mice/genotype
for all genotypes except Mx1-cre Srsf2fl/WT, where n = 5; pIpC was administered to recipient mice 4 weeks following transplantation).
(F and G) H&E staining of femurs (scale bars, 50 mm) (F) and peripheral blood smears (G) from Mx1-cre Srsf2WT, Mx1-cre Srsf2fl/fl, or Mx1-cre Srsf2P95H/WT
mice (scale bars, 10 mm). A representative neutrophil (left) and erythroid precursor (right) is shown for Srsf2 WT and KO mice. Mx1-cre Srsf2P95H cells were
marked by hypolobated and hypogranulated neutrophils (left two photos) and nuclear irregularities as well as cytoplasmic vacuolization and blebbing of erythroid
precursors (right two photos).
Error bars represent mean ± SD. ***p < 0.001; ****p < 0.0001. See also Figure S1.Given that mutations in SRSF2 occur as early genetic events in
MDS pathogenesis (Papaemmanuil et al., 2013) and that MDS is
characterized by expansion of HSPCs, we next examined HSPC
numbers and function in Srsf2P95H mice. Analysis of CD45.2+HSPC subsets fromMx1-cre Srsf2P95H/WT mice and littermate
controls 14 weeks after pIpC injection revealed expansion of
lineage-negative Sca1+ c-Kit+ (LSK) and restricted hematopoi-
etic progenitor cells (LSK CD48+ CD150+; hematopoieticCancer Cell 27, 617–630, May 11, 2015 ª2015 Elsevier Inc. 619
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Figure 2. Conditional Expression of Srsf2P95H Results in Expansion of Hematopoietic Stem and Progenitor Cells with Increased Cell
Proliferation and Apoptosis
(A and B) Enumeration (A) and fluorescence-activated cell sorting (FACS) analysis (B) of BM LSK cells, long-term hematopoietic stem cells (LT-HSC), restricted
hematopoietic progenitor cell fractions 1 (HPC-1) and 2 (HPC-2), andmultipotent progenitor (MPP) cells (Oguro et al., 2013) in 12-week-oldMx1-cre Srsf2WTand
Mx1-cre Srsf2P95H/WT mice (n = 5 mice/genotype).
(C) Cell cycle analysis of LSK cells fromMx1-cre Srsf2WT orMx1-cre Srsf2P95H/WTmice with in vivo bromodeoxyuridine (BrdU) administration. A representative
FACS plot analysis shows gating on LSK cells followed by BrdU versus 4’,6-diamidino-2-phenylindole (DAPI) stain (left).
(D) Relative quantification of the percentage of LSK cells in S, G2M, and G1 phase is shown on the right (n = 8 mice per group).
(E) Relative quantification of the percentage of Annexin V+/DAPI LSK cells (n = 8 mice/genotype). C, control; KI, knockin.
Error bars represent mean ± SD. *p < 0.05, **p < 0.01, ****p < 0.0001. See also Figure S2.progenitor cell fraction 2 [HPC-2]; Oguro et al., 2013) in mutant
mice relative to controls (Figures 2A and 2B). A similar LSK
expansion was seen in spleens of Srsf2P95H mutant mice
(although splenomegaly was not observed up to 20 weeks
post-pIpC) (Figures S2A and S2B). Because the detection of
increased HSPCs in Srsf2P95Hmutant mice appeared paradox-
ical given the decreased peripheral blood counts in these same
mice, we next examined the cell cycle kinetics and apoptosis of
Srsf2mutant HSPCs. Indeed, Srsf2P95H LSK cells were charac-
terized by an increase in the proportion of cells in S-phase aswell
as in early apoptosis (Figures 2C–2E). Despite HSPC expansion
in Srsf2P95H mutant mice, purified LSK cells from mice with a
homozygous Srsf2 deletion or heterozygous Srsf2P95H muta-
tion had similarly impaired colony formation and serial re-plating
capacity in vitro (Figure S2C).620 Cancer Cell 27, 617–630, May 11, 2015 ª2015 Elsevier Inc.To assess the functional effects of Srsf2 alterations on HSC
self-renewal in vivo, we next compared Srsf2 heterozygous KO,
homozygous KO, and heterozygous P95H mutant mice in
competitive transplantation assays (Figure 3A). Equal numbers
of BM MNCs from CD45.1 WT mice and CD45.2 Mx1-cre Srsf2
WT, Mx1-cre Srsf2fl/WT, Mx1-cre Srsf2fl/fl, or Mx1-cre
Srsf2P95H/WT mice were transplanted into lethally irradiated
CD45.1 mice, followed by pIpC injection 4 weeks later. An
assessment of peripheral blood chimerismmonthly thereafter re-
vealeda complete lossofCD45.2 chimerism inmice transplanted
withMx1-cre Srsf2fl/fl cells and a significant decrease in chime-
rism inmice transplanted withMx1-cre Srsf2P95H/WT cells (Fig-
ure 3B; Figures S3A and S3B). However, an analysis of BM LSK
chimerism 18 weeks post-transplant revealed an increase in
CD45.2+ HSPCs derived from Srsf2P95H mice relative to other
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Figure 3. Srsf2P95H Mutation Impairs Hematopoietic Stem Cell Self-Renewal in a Manner Distinct from Srsf2 Loss
(A) Depiction of a competitive BM transplantation assay. pIpC, polyinosinic-polycytidylic acid.
(B) Percentage of CD45.2+ chimerism in the peripheral blood of recipient mice (n = 10 mice/genotype).
(C and D) Chimerism (C) and flow cytometric enumeration (D) of CD45.2+ LSK (left) and MP (lineage-negative Sca1-c-Kit+, right) cells in the BM of Mx1-cre
Srsf2WT, Mx1-cre Srsf2fl/WT, Mx1-cre Srsf2fl/fl, and Mx1-cre Srsf2P95H/WT mice 14 weeks after pIpC injection.
Error bars represent mean ± SD. **p < 0.001, ***p < 0.0002, ****p < 0.0001. See also Figure S3.groups and a near complete absence of CD45.2+ HSPCs from
Srsf2fl/flmice (Figures 3Cand3D;FigureS3C). Serial competitive
transplantationofwholebonemarrow fromSrsf2P95H,Srsf2het-
erozygous KO, andSrsf2WTprimary recipient transplantedmice
continued to reveal an impaired reconstitution capacity of
Srsf2P95Hmutantmice relative toSrsf2heterozygousKOorcon-
trol mice (Figure S3D). Of note, colony assays and competitive
transplantation experiments were performed using multiple ge-
notypes of control mice (Cre-negative Srsf2P95H mice as well
as Mx1-cre Srsf2 WT mice; Figures S2C and S3E) to control for
any possible confounding effect of Cre expression or the pres-
ence of the unexcised P95H knockin allele.
The fact that Mx1-cre Srsf2P95H/WT mice had an increase in
HSPCs despite impaired formation of mature peripheral blood
cells suggested that mutant Srsf2 was associated with impaired
HSPC differentiation. Flow cytometric analysis of mature and in-termediate precursor cell subsets in Srsf2P95H mice was there-
fore performed to identify the stage of impaired hematopoiesis.
This revealed that peripheral leukopenia was predominantly
due to decreased peripheral blood B cells, evident at all stages
of B lymphopoiesis following the transition of pre-proB to proB
cells, in Srsf2P95H mice relative to controls (Figures S3F and
S3G).Moreover, immunophenotypic analysis of intermediate he-
matopoietic progenitors (Pronk et al., 2007) revealed deficits in
early erythroid progenitors in Srsf2P95H mice relative to con-
trols, initiating at the pre-MegE and pre-colony-forming units,
erythroid, stages (Figures S3H and S3I). Given prior data
showing that homozygous deletion of Srsf2 resulted in defective
T cell maturation and CD45 splicing (Wang et al., 2001), we also
examined thymic T cell differentiation and CD45 isoform expres-
sion in Srsf2P95H mice relative to controls (Figures S3J and
S3K). This revealed no effect of Srsf2P95H mutation on thymicCancer Cell 27, 617–630, May 11, 2015 ª2015 Elsevier Inc. 621
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T cell maturation or protein expression of the specific CD45 iso-
forms identified previously to be downregulated with homozy-
gous deletion of Srsf2 (Wang et al., 2001).
Collectively, the biological analysis of Srsf2P95H mutant mice
identified phenotypes distinct from mice with a partial or com-
plete loss of Srsf2, suggesting that SRSF2 mutations alter
SRSF2’s normal function rather than resulting in haploinsuffi-
ciency or a dominant-negative function. Of note, despite the
impaired hematopoietic differentiation, increase in HSPC sub-
sets, and morphologic dysplasia in Srsf2P95H/WT mice, no
Srsf2P95H mutant mice developed acute myeloid leukemia in
up to 70 weeks of observation.
SRSF2Mutations AreAssociatedwithGlobal Alterations
of Gene Expression and Splicing
Wenext sought to identify the transcriptional and post-transcrip-
tional alterations caused by SRSF2 mutations through RNA-seq
of purified LSK and myeloid progenitor (MP, lineage-negative
Sca1- c-Kit+) populations. This was performed 4 weeks after
pIpC administration. In an unsupervised cluster analysis based
on coding gene expression, samples clustered first by cell type
and then by genotype (Figure S4A). The expression of several he-
matopoietic regulators was altered in Srsf2P95H mutant cells,
including upregulation of Gfi1, Cebpe, and Hoxb2 in LSK cells;
downregulation of Gata1 and Gata2 in MP cells; and downregu-
lation of Cdkn1a in both populations. In addition, we observed
preferential down- versus upregulation of the expression of cod-
ing genes in Srsf2 mutant cells relative to the WT (Figures S4B
and S4C). Gene ontology (GO) analysis revealed an enrichment
for the downregulation of genes in both LSK and MP cells
involved in the regulation of cell cycle, proliferation, differentia-
tion, and apoptosis (upregulated genes were not enriched for
these processes; Figure S4D).
To identify changes in splicing driven by SRSF2mutations that
might contribute to disease, we augmented our mouse data with
RNA-seq data from primary CMML (n = 13; 3 with SRSF2 muta-
tion) and AML (n = 9, 5 with SRSF2 mutation) patient samples
(Table S1) as well as K562 cells ectopically expressing an empty
vector or a single allele ofSRSF2 (WT, P95H, P95L, and P95R). In
all sequenced patients with SRSF2 mutations, the WT and
mutant alleles were expressed at similar levels (Table S1), as
was the case for the Srsf2P95H mouse cells (Figure 1). Similarly,Figure 4. SRSF2 Mutations Alter Exonic Splicing Enhancer Preference
(A) Scatterplot of cassette exon inclusion in K562 cells expressing empty vector or
exons with increased or decreased inclusion. Red and blue dots represent individu
vector cells, respectively. Promoted and repressed cassette exons are defined
Bayes factor ofR5, as estimated by Wagenmakers’ framework (Wagenmakers
(B) Enriched (right) and depleted (left) k-mers in cassette exons promoted versus
(C) Scatterplot of cassette exon inclusion in TF-1 cells following transfection wit
Percentages indicate the percent of alternatively spliced cassette exons with inc
(D) Enriched (right) and depleted (left) k-mers in cassette exons promoted versus
(E)Mean enrichment of all variants of the SSNGmotif in cassette exons promoted v
MP cells expressing WT or mutant SRSF2. Error bars indicate 95% confidence i
(F) Relative frequency of CCNG and GGNGmotifs in cassette exons promoted ve
and primary AML and CMML samples with or without SRSF2 mutations (right) (th
indicates 95% confidence interval by bootstrapping. The schematic illustrates a p
left to right, the features are the upstream exon (gray box) and intron (black line), t
(black line) and exon (gray box). Horizontal axis, genomic coordinates defined with
relative frequency of the indicated motifs over genomic loci containing cassette
See also Figure S4.isogenic K562 cells with lentiviral expression of WT or mutant
SRSF2 cells expressed WT and mutant SRSF2 at roughly equal
levels (Figures S4E–S4G). We quantified global changes in
splicing of 125,000 alternative splicing events and 160,000
constitutive splice junctions associated with SRSF2 mutations
in these five datasets (LSK, MP, CMML, AML, and K562). We
required a minimum change in isoform ratio of 10% to call an
event differentially spliced (where a change in isoform ratio is
defined as an absolute, rather than relative, quantity as the in-
crease or decrease in the percentage of all mRNAs transcribed
from the parent gene that follow a given splicing pattern). In all
datasets, SRSF2 mutations were associated with differential
splicing of all classes of splicing events as well as novel alterna-
tive splicing and intron retention of splice junctions annotated as
constitutively spliced. However, only a relatively small fraction of
alternatively spliced events of any class were affected by SRSF2
mutations (Figure S4H). SRSF2 mutations were associated with
a mild bias toward exon skipping but did not lead to globally
increased levels of predicted substrates for degradation by
nonsense-mediated decay.
SRSF2 Mutations Alter Exonic Splicing Enhancer
Preference but SRSF2 Loss Does Not
Because SRSF2 normally recognizes ESE elements within the
pre-mRNA to promote exon recognition (Graveley and Maniatis,
1998; Liu et al., 2000; Schaal and Maniatis, 1999; Zahler et al.,
2004), we hypothesized that SRSF2 mutations might alter its
normal sequence-specific activity. To test this, we performed
an ab initio motif identification screen. We quantified the occur-
rence of each possible k-mer (k = 4, 5, 6) within cassette exons
that were differentially spliced in Srsf2P95H MP cells and identi-
fied k-mers that were enriched or depleted in cassette exons
promoted versus repressed in Srsf2P95H cells. We identified en-
riched and depleted motifs using a non-parametric (Kolmo-
gorov-Smirnov) statistical test with a p value threshold of 0.05.
Significantly enriched k-mers were C-rich, whereas depleted
k-mers were G-rich (Figures S4I and S4J). We then performed
an identical analysis using our K562 data, which likewise identi-
fied CCAG and GGTG as the most enriched and depleted
consensus motifs, respectively (Figures 4A and 4B). A recent so-
lution structure of SRSF2 in complex with RNA revealed that
SRSF2 has a consensus motif of SSNG (where ‘‘S’’ representsSRSF2P95R. Percentages indicate the percent of alternatively spliced cassette
al cassette exons that are promoted or repressed inSRSF2P95R versus empty
as those whose inclusion levels are increased or decreased by R10% with a
et al., 2010).
repressed in SRSF2P95R versus WT cells.
h a siRNA against SRSF2 or a control non-targeting siRNA (KD, knockdown).
reased or decreased inclusion.
repressed in SRSF2 KD versus control cells.
ersus repressed in TF-1 cells following SRSF2 knockdown andK562, LSK, and
ntervals estimated by bootstrapping.
rsus repressed by SRSF2mutations in LSK and MP cells (top), K562 cells (left),
e sample numbers correspond to the patient identifiers in Table S1). Shading
ortion of a metagene containing the differentially spliced cassette exon. From
he cassette exon (black box, vertical dashed lines), and the downstream intron
respect to the 50 and 30 splice sites where 0 is the splice site itself. Vertical axis,
exons promoted versus repressed by SRSF2 mutations (log scale).
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C or G) and efficiently recognizes both CCNG and GGNG (Daub-
ner et al., 2012). Therefore, our ab initio analysis suggested that
mutations affecting the P95 residue may alter SRSF2’s ability to
recognize variants of its normal SSNG motif.
To further explore this hypothesis, we compared the relative
enrichment of all four SSNG variants in cassette exons that
were differentially spliced upon depletion of SRSF2, overexpres-
sion of WT SRSF2, or expression of mutant SRSF2. SRSF2
depletion—achieved by knockdown of endogenous SRSF2 in
the absence of mutant protein expression (Figure S4K)—caused
preferential skipping of cassette exons, consistent with SRSF2’s
canonical role in promoting exon recognition (Figure 4C). Ab ini-
tio motif analyses identified both C- and G-rich variants of the
SSNG motif as the most enriched motifs in cassette exons that
were repressed following SRSF2 depletion (Figure 4D). Quantita-
tion of the enrichment of each SSNG variant revealed that all
were associated with exon repression following knockdown. In
contrast, overexpression of WT SRSF2 was associated with
enrichment of each SSNG variant (Figure 4E). These data sug-
gest that different SSNG variants function as equally efficacious
SRSF2-dependent ESEs, consistent with SRSF2’s in vitro bind-
ing specificity (Daubner et al., 2012). In contrast, K562 cells as
well as LSK and MP cells expressing mutant Srsf2 exhibited
enrichment for CCNG and depletion for GGNG in exons that
were promoted versus repressed (Figure 4E).
To test whether this motif enrichment and depletion was due
to ESE activity, we computed the spatial distribution of CCNG
and GGNG motifs across genomic loci containing cassette
exons that were promoted or repressed in association with
SRSF2 mutations. CCNG and GGNG were, respectively, en-
riched and depleted specifically over cassette exons and not
over the flanking introns or exons. We observed similar motif
preferences and distributions in patient transcriptomes (Fig-
ure 4F). Because CCNG/GGNG motifs were not consistently
enriched/depleted in introns flanking differentially spliced
cassette exons, and because we were unable to identify en-
riched motifs with ab initio searches in introns, we conclude
that differential cassette exon splicing is likely due primarily to
altered recognition of exonic motifs. Together, these data reveal
spatially restricted enrichment of specific ESEs in association
with SRSF2 mutations and suggest that SRSF2 mutations
cause alteration rather than loss of normal ESE recognition
activity.
SRSF2 Proline 95 Mutations Alter RNA Binding
Specificity by Changing the Conformation of Both RRM
Termini
We next tested whether this association between SRSF2 muta-
tions and enrichment/depletion of specific ESEs was due to
altered SRSF2:RNA interactions. We purified SRSF2’s RNA
RRM as described previously and performed isothermal titration
calorimetry (ITC) with the RNA ligand 50-uCCAGu-30, an optimal
SRSF2 target according to the SSNG consensus sequence
(Daubner et al., 2012). All three P95 mutations resulted in an in-
crease in binding affinity of 3.9- to 4.5-fold relative to WT SRSF2
(Figures 5A and 5B; Figure S5A), consistent with the enrichment
for CCNGmotifs that we observed in exons promoted by SRSF2
mutations (Figure 4B). We next tested whether P95 mutations
resulted in altered RNA binding specificity. In contrast to624 Cancer Cell 27, 617–630, May 11, 2015 ª2015 Elsevier Inc.50-uCCAGu-30 RNA, ITC measurements revealed that all three
P95 mutants exhibited a 1.2- to 2.1-fold decrease in binding af-
finity to the 50-uGGAGu-30 RNA relative toWT SRSF2 (Figures 5A
and 5B; Figure S5B). ITC measurements using the RNA se-
quences 50-uGCAGu-30 and 50-uCGAGu-30 revealed that G > C
substitutions at the second motif position resulted in larger in-
creases in binding affinity than at the first motif position (2.6- to
3.4-fold versus 1.1- to 1.8-fold; Figure 5B; Figures S5C and
S5D). The RNA binding preferences measured by ITC were
remarkably consistent with the ESE enrichment identified by
RNA-seq. For each mutant, the level of motif enrichment (Fig-
ure 4E) was roughly proportional to the affinity increase (Fig-
ure 5C), and the enrichment and affinity measurement supported
the same relative preference for each specific motif (CC > GC >
CG > GG). This strongly supports the notion that the splicing
changes caused by P95 mutations are the result of an altered
sequence specificity of the SRSF2 RRM.
P95 is located at the C-terminal end of the SRSF2 RRM, and
the published solution structure of SRSF2 in complex with 50-uC-
CAGu-30 revealed extensive contacts of P95 with the second
cytosine (Figure S5E), emphasized by several intermolecular nu-
clear Overhauser effects (NOEs) (Daubner et al., 2012). To test
whether SRSF2’s RNA binding surface was altered by P95 mu-
tations, we conducted nuclear magnetic resonance (NMR) titra-
tion with the SRSF2 P95H RRM and the 50-uCCAGu-30 RNA and
assigned the backbone of this complex using standard hetero-
nuclear NMR experiments. Mapping of the chemical shift pertur-
bations revealed that the RNA-binding surface of the RRM is not
disturbed by the P95H mutation. However, both termini experi-
enced large changes in their environment (Figure 5D), an obser-
vation that held true for all three P95 mutations (Figure S5F).
Consistent with our ESE and ITC analyses, this relocation of
termini primarily affected the second cytosine, which exhibited
the largest chemical shift perturbations of its proton resonances
(Figures S5G and S5H). Smaller changes of chemical shifts were
observed when P95 mutants were bound to 50-uGGAGu-30 (Fig-
ure S5H). Together, our experiments indicate that SRSF2 muta-
tions change SRSF2’s normal RNA-binding affinity and speci-
ficity in vitro, likely explaining the widespread alterations in
ESE preference we observed in vivo.
Mutant SRSF2 Promotes Mis-splicing and Degradation
of EZH2
We next used our transcriptome data to identify common
changes in splicing driven by SRSF2 mutations that might
contribute to disease. Intersection of differentially spliced genes
in LSK, MP, CMML, and AML samples identified 75 genes differ-
entially spliced in association with SRSF2mutations in both LSK
andMP cells and at least one primary patient cohort as well as an
additional 97 (LSK) and 87 (MP) genes differentially spliced in one
mouse cell population, but not the other, as well as a patient
cohort (Figure 6A; Tables S2–S5). Many of these genes have a
known importance in myeloid malignancies. For example,
SRSF2 mutations promoted the inclusion of a highly conserved
‘‘poison’’ cassette exon of EZH2 (Enhancer of zeste homolog
2) and repressed a frame-preserving cassette exon of BCOR
(BCL6 corepressor) (Figure 6A; Figures S6A and S6B). Of note,
we did not identify altered splicing of CD45 in SRSF2 mutant
cells (Tables S2–S5), which has been noted previously as being
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Figure 5. Proline 95 Mutations Change the RNA-Binding Specificity of the SRSF2 RNA RRM In Vitro and Lead to Relocation of the N and C
Termini
(A) ITC raw data and binding curve for the SRSF2 RRM P95H mutant with 50-uCCAGu-30 and 50-uGGAGu-30 RNA.
(B) Change in RNA-binding affinity (percent) for SRSF2 RRM P95H (blue), P95L (green), and P95R (black) mutants compared with WT (red) (Daubner et al., 2012)
using RNA targets 50-uCCAGu-30, 50-uGCAGu-30, 50-uCGAGu-30, and 50-uGGAGu-30.
(C) Change in RNA-binding specificity of SRSF2 RRM WT, P95H, P95L, and P95R with 50-UCCAGU-30 (blue), 50-UGCAGU-30 (dark gray), 50-UCGAGU-30 (light
gray), and 50-UGGAGU-30 RNA (orange). Error bars represent mean ± SD.
(D) Left: overlay of 2D [15N-1H] heteronuclear single quantum coherence (HSQC) of the wild-type (red) and P95Hmutant (blue) bound to 50-UCCAGU-30 RNA, with
negative peaks shown in green (WT) and light green (mutant). Right: difference of the chemical shift perturbations of the P95H mutant and wild-type. Positive
values (blue) with a higher perturbation with the P95Hmutant and negative values (red) with a higher perturbation with theWT are shown.Missing assignments are
marked with gray bars and proline with a gray P. Residues with the highest difference are depicted in both the graph and spectra.
See also Figure S5.altered in murine Srsf2 KO hematopoietic cells (Wang et al.,
2001).
To identify potential functional consequences of recurrent
mis-splicing, we focused on the splicing event in EZH2.
SRSF2 mutant cells exhibited preferential inclusion of a poison
cassette exon that introduces a premature termination codon
predicted to result in nonsense-mediated decay (NMD) of
EZH2 (Figures 6B and 6C). Both the poison exon itself and its
flanking intronic sequences exhibited high sequence conserva-
tion across vertebrates, exceeding the sequence conservation
exhibited by the upstream and downstream constitutive coding
exons themselves, which is a common feature of physiologi-
cally important splicing events (Lareau et al., 2007; Ni et al.,
2007; Figure 6B).We validated this EZH2 splicing change using both qualitative
and quantitative isoform-specific RT-PCR in leukemia cell lines
that were WT or mutant for SRSF2 (Figures S6C and S6D) as
well as in an independent panel of primary AML patient samples
with or without SRSF2mutations (n = 8, 4 with SRSF2mutations;
Figure 6D; Figure S6E).
Next, to confirm whether the cassette exon promoted by
SRSF2 mutations triggers degradation by NMD, we measured
the half-life of the inclusion isoform of EZH2 in SRSF2P95H cells
transfected with a control or anti-UPF1 (a required NMD factor)
short hairpin RNA (shRNA) following transcriptional shutoff with
actinomycin D (’t Hoen et al., 2011; Figure 6E; Figures S6F and
S6G). The fact that the mRNA half-life of the inclusion isoform
of EZH2 was lengthened by UPF1 knockdown in theseCancer Cell 27, 617–630, May 11, 2015 ª2015 Elsevier Inc. 625
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experiments suggests that this particular isoform of EZH2, which
is promoted bymutant SRSF2, undergoes NMD. The half-life of a
well-characterized NMD substrate of SRSF3 (Lareau et al., 2007;
Ni et al., 2007) increased similarly following UPF1 knockdown,
confirming that UPF1 knockdown effectively inhibited NMD
(Figure S6H).
Next, to identify whether the protein product of EZH2 is altered
in SRSF2 mutant cells, we performed WB analysis of a panel of
human AML cell lines WT (TF-1, K562) or mutant for SRSF2
(K052) (all WT for EZH2). This revealed lower EZH2 protein levels
as well as lower global levels of histone H3 lysine 27 trimethyla-
tion (H3K27me3, a methylation mark placed by EZH2) in SRSF2
mutant K052 cells (Figure 6F). To further validate this finding in an
isogenic context, we performedWBanalysis in K562 cells ectop-
ically expressing WT SRSF2 or SRSF2P95H/L/R mutant cDNA.
This analysis revealed a consistent downregulation of EZH2
protein expression as well as global H3K27me3 in all three
SRSF2 mutant samples compared with SRSF2 WT K562 cells
(Figure 6G).
Consistent with SRSF2 mutations promoting a disabling
splicing change in EZH2, EZH2 loss-of-function mutations are
common in MDS. In an analysis of >1,800 MDS patients where
EZH2 and SRSF2 were both sequenced, EZH2 loss-of-function
mutations were mutually exclusive with SRSF2 mutations (p <
0.0001) (Bejar et al., 2012; Ernst et al., 2010; Haferlach et al.,
2014; Muto et al., 2013; Papaemmanuil et al., 2013; Figure 6H).
The above data strongly link SRSF2 mutations to disabling
splicing of EZH2. We next sought to examine whether the
change in RNA ESE preference induced by SRSF2 mutations
caused EZH2mis-splicing. We therefore cloned the genomic lo-
cus containing the EZH2 poison exon and flanking introns and
constitutive exons to create a minigene that recapitulates this
splicing event. We identified three potential SRSF2-dependent
SSNG motifs in the poison exon (CCTG, CCTG, and GCAG),
one or more of which we expected to be better recognized by
mutant SRSF2 than WT SRSF2. We then mutated each motif
to the corresponding GG equivalent, both separately and in
combination (Figure 6I). Measuring cassette exon recognitionFigure 6. SRSF2 Mutant Primary Murine and Patient Samples Exhibit C
(A) Intersection of genes exhibiting differential splicing in SRSF2mutant versus W
orthologous genes).
(B) IntegrativeGenomics Viewer (IGV)/Sashimi plot illustrating theEZH2 cassette e
patient numbers listed in the Sashimi plot correspond to the numbers in Table S1
as estimated by phastCons (Siepel et al., 2005), across 30 vertebrate species is
(C) Bar plot describing the percentage of EZH2 transcripts harboring a specific c
RNA-seq data. Error bars indicate 95% confidence intervals.
(D) RT-PCR of an EZH2 exon inclusion event in an independent set of SRSF2 W
(E) Quantitative RT-PCR of EZH2 inclusion isoform in SRSF2P95H mutant cell lin
(F) WB analysis for EZH2 and H3K27me3 in SRSF2/EZH2 WT (TF-1, K562) and S
(G) WB analysis for EZH2, H3K27me3, and FLAG epitope in K562 cells with le
SRSF2P95L, or SRSF2P95R (left). Relative quantification of EZH2 protein expre
mutants relative to WT is shown on the right.
(H) EZH2 and SRSF2mutations are mutually exclusive in the sequencing of DNA f
2014; Muto et al., 2013; Papaemmanuil et al., 2013).
(I) Schematic of the EZH2 cassette exon with SSNG motifs highlighted and muta
(J) EZH2 cassette exon inclusion for minigenes containing the endogenous cass
equivalent.
(K) Photographs (left) and enumeration (right) of c-Kit+/ZsGreen1+ cells from Srsf
cDNA and plating in methylcellulose medium.
**p < 0.01, ****p < 0.0001. Error bars represent mean ± SD unless stated otherwin K562 cells expressing WT or mutant SRSF2, we found that
the first motif was required for robust splicing change in
SRSF2mutant cells, such that the mutation CCTG > GGTG pre-
vented an increase in poison exon recognition (Figure 6J). We
conclude that SRSF2 mutations induce a disabling splicing
change in EZH2 in an ESE-dependent manner, consistent with
altered RNA recognition activity.
We next sought to test whether restoring normally spliced
EZH2 mRNA could rescue hematopoiesis in SRSF2 mutant
cells. EZH2 full-length cDNA or an empty vector (both in a
retroviral ZsGreen1 vector) were overexpressed in c-Kit+
Srsf2P95H or WT cells, followed by assessment of methylcellu-
lose colony formation of c-Kit+/ZsGreen1+ cells. EZH2 cDNA
was equally overexpressed in Srsf2 mutant and WT cells (Fig-
ure S6I), and Srsf2P95H mutant cells overexpressing full-length
EZH2 experienced an 50% increase in colony formation rela-
tive to Srsf2P95H mutant cells expressing an empty vector (Fig-
ure 6K; Figure S6J). In contrast, EZH2 overexpression had no
substantial effect on initial colony formation in Srsf2 WT cells
(Figure 6K; Figure S6I). These data identify that restoration of
normally spliced EZH2 mRNA in SRSF2 mutant cells at least
partially rescues the hematopoietic defects induced by mutant
SRSF2.
DISCUSSION
The consistent occurrence of heterozygous point mutations
affecting highly restricted residues of spliceosomal proteins
strongly suggests a gain-of-function or dominant-negative activ-
ity for these mutations in malignant transformation. Here we
identify an effect of the SRSF2P95H mutation distinct from loss
ofSRSF2 and reveal thatmutations inSRSF2 confer an alteration
in function that results in key aspects of MDS. This includes an
increase in HSPCs in Srsf2P95H mutant mice with impaired dif-
ferentiation, altered cell cycle kinetics, and increased apoptosis
resulting in peripheral cytopenias andmorphologic dysplasia. By
contrast, WT Srsf2 appears to be constitutively required for
hematopoiesis.onvergent Splicing Alterations
T mouse LSK and MP cells and primary AML and CMML samples (restricted to
xon promoted bySRSF2mutations inmultiple datasets analyzed here (top) (the
detailing patient characteristics). The DNA sequence conservation of the locus,
shown in the track below the Sashimi plot.
assette exon in the SRSF2 mutant relative to WT primary AML samples from
T and mutant AML samples.
e K052 cells with or without UPF1 knockdown and actinomycin D treatment.
RSF2P95H mutant/EZH2 WT (K052) AML cell lines.
ntiviral overexpression of N-terminal FLAG-tagged SRSF2 WT, SRSF2P95H,
ssion by WB to total histone H3 expression in K562 cells expressing SRSF2
rom >1,000 MDS patients (Bejar et al., 2012; Ernst et al., 2010; Haferlach et al.,
tions to GG equivalents shown.
ette exon or a cassette exon with mutation of motifs 1, 2, and/or 3 to the GG
2WT or Srsf2P95Hmice 14 days after overexpression of empty vector or EZH2
ise. See also Figure S6 and Tables S1–S5.
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Transcriptional analysis of SRSF2 mutant cells revealed that
SRSF2mutations result in genome-wide alterations in ESE pref-
erence in both human and murine cells. Biochemical analysis of
the interaction of SRSF2 with RNA in cell-free in vitro assays
identified an analogous change in specificity of interactions be-
tween SRSF2 and pre-mRNA induced by SRSF2 mutations.
This altered interaction of mutant SRSF2 with RNA appears to
be due to an effect of SRSF2P95H/L/R mutations on the confor-
mations of the termini of SRSF2’s RRM domain, as revealed by
NMR spectroscopy. Our genomic and biochemical assays indi-
cate that SRSF2 mutations cause alteration rather than loss-of-
function, driving preferential recognition of cassette exons
containing C- versus G-rich ESEs.
The altered pre-mRNA recognition activity of mutant SRSF2
likely underlies the mis-splicing of key transcriptional regula-
tors—several of which have been implicated previously in
MDS pathogenesis. This includes promotion of a poison exon
of EZH2 that undergoes NMD and results in reduced EZH2 pro-
tein expression in SRSF2 mutant cells. Loss-of-function muta-
tions in EZH2 occur in the same exact spectrum of myeloid
malignancies as SRSF2 mutations (Ernst et al., 2010; Nikoloski
et al., 2010) and loss of Ezh2 has been functionally linked to
MDS development in vivo (Muto et al., 2013). Moreover,
SRSF2 and EZH2 mutations are mutually exclusive in MDS pa-
tients (Haferlach et al., 2014; Papaemmanuil et al., 2013), but
the basis for this observation was previously unknown. The
data here provide a mechanistic basis for this mutual exclusiv-
ity as SRSF2 mutations functionally reduce EZH2 protein
expression.
In addition to the effects of mutant SRSF2 on EZH2 splicing
and protein expression, a number of other genes of known
importance in hematopoiesis and malignancy were also consis-
tently differentially spliced in isogenic human cells, primary pa-
tient samples, and murine cells bearing mutant SRSF2. These
include additional genesmutated inMDS (such asBCOR), genes
with an importance in hematopoietic stem cell self-renewal (such
as IKAROS), and genes critical for cell survival (such as
CASPASE 8). Future efforts to understand the functional effects
of each of these specific splicing events will be important in
further delineating the effects of mutant SRSF2 on MDS patho-
genesis as well as possibly providing novel means for therapeu-
tic targeting of SRSF2 mutant cells.
Our studies, which reveal bothmechanistic splicing alterations
and specific mis-spliced isoforms in SRSF2 mutant cells, may
provide insights into therapeutic opportunities for targeting
SRSF2 mutant cells. For example, the observations that mutant
SRSF2 promotes the inclusion of a poison exon in an ESE-
dependent manner and that restoration of normally spliced
EZH2 mRNA partially rescues defective hematopoiesis in
SRSF2 mutant cells suggest that normal cellular function may
be at least partially restored by manipulating specific pathologic
splicing events.
EXPERIMENTAL PROCEDURES
Generation of the Srsf2P95H conditional knockin mice is described in the Sup-
plemental Experimental Procedures. All animal procedures were conducted in
accordance with the Guidelines for the Care and Use of Laboratory Animals
and approved by the Institutional Animal Care and Use Committees at Memo-
rial Sloan Kettering Cancer Center.628 Cancer Cell 27, 617–630, May 11, 2015 ª2015 Elsevier Inc.Patient Samples
Studies were approved by the Institutional Review Boards of Memorial Sloan
Kettering Cancer Center and Fred Hutchinson Cancer Research Center and
conducted in accordance to the Declaration of Helsinki protocol. Informed
consent was obtained from all human subjects.
mRNA Sequencing
For sorted mouse cell populations, K562 cells, and primary AML and CMML
samples, RNAwas extracted usingQIAGENRNeasy columns. poly(A)-selected,
unstranded Illumina libraries were prepared with a modified TruSeq protocol.
0.53AMPure XPbeadswere added to the sample library to select for fragments
of <400 bp, followed by 13 beads to select for fragments of >100 bp. These
fragments were then amplified with PCR (15 cycles) and separated by gel elec-
trophoresis (2%agarose). 300-bpDNA fragmentswere isolated and sequenced
on the Illumina HiSeq 2000 (100 million 2 3 49 bp reads/sample).
RNA-Seq Read Mapping
Reads were mapped to the University of California, Santa Cruz (UCSC)
hg19 (NCBI GRCh37) human genome or UCSC mm10 (NCBI GRCm38)
genome assemblies. First, a modified version of RNA-seq by expectation
maximization (RSEM) that called Bowtie v1.0.0, with the v 2 argument
was created. This modified RSEM was then called with the arguments
‘--bowtie-m 100--bowtie-chunkmbs 500 --calc-ci --output-genome-bam’
on the gene annotation file. Read alignments with MAPping Quality
(MAPQ) scores of 0 and/or a splice junction overhang of less than 6 bp
were then filtered out. The remaining unaligned reads were then
aligned by TopHat v2.0.8b with the arguments ‘--bowtie1 --read-mis-
matches 2 --read-edit-dist 2--no-mixed --no-discordant --min-anchor-
length 6 --splice-mismatches 0 --min-intron-length 10 --max-intron-length
1000000 --min-isoform-fraction 0.0 --no-novel-juncs --no-novel-indels
--raw-juncs’ on the splice junction file (--mate-inner-dist and --mate-std-
dev were calculated by mapping to constitutive coding exons with the
Mixture of Isoforms (MISO) exon_utils.py utility). The resulting TopHat
alignments were then filtered as for the RSEM-generated alignments. Finally,
the RSEM- and TopHat-created binary sequence alignment/map (BAM) files
were merged to create final BAM files.
Isoform Expression Measurements
Two different methods were used to quantify isoform ratios. For alternative
splicing events from MISO’s v2.0 annotation, MISO was used to estimate iso-
form ratios. For alternative splicing or intron retention of annotated constitutive
junctions, junction reads alone were used as described previously (Hubert
et al., 2013). To identify differentially expressed events, we required aminimum
of 20 identifying reads (supporting either, but not both, isoforms) per event as
well as a change in isoform ratioR 10%. For the LSK, MP, and K562 data, we
used two-sample statistical comparisons (Wagenmakers’ framework; Bayes
factorR 5);]. For the AML and CMML data, we used group statistical compar-
isons (Mann-Whitney U test, p% 0.05). Real-time PCR was used to measure
EZH2 cassette exon inclusion as described in the Supplemental Experimental
Procedures.
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